To: Oncologic Drugs Advisory Committee Members and Guests
From: Richard Pazdur, M.D.
Director, Division of Oncology Drug Products, CDER, FDA
The Division of Oncology Drug Products has chosen to convene a session of the Oncologic Drugs Advisory Committee on July 27th to seek your assistance and advice on an oncology drug product. We have provided this background package in order to assist you in your discussion. It includes documents that review the application related to both clinical and statistical data.
Documents in this background package include:
FDA Clinical Review:
TAB 1 Cinical Review of NDA 21-677 Alimta (pemetrexed), Eli Lilly & Co.
FDA Statistical Review:
TAB 2 Statistical Review of NDA 21-677 Alimta (pemetrexed), Eli Lilly & Co.
We greatly appreciate your participation in this discussion and look forward to seeing
you in July.